ClinicalTrials.gg
RecruitingNCT07858864GLP1-SARCOUpdated Oct 8, 2026

GLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without Diabetes

An observational study in Obesity and Sarcopenia, sponsored by Istanbul Saglik Bilimleri University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Istanbul Saglik Bilimleri University · Observational

How we know · 4 judgments

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Updated Oct 8, 2026Primary outcomes revisedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
42
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 353 studies in Obesity with a site in Turkey — 73 open to participants now, 90 under way, 16 of them phase 3. Obesity · Turkey.

Planned enrollment
126th of 160
42 · median 82
Started
2026
with 59 others
Observational
160 of 353
32 open now
Primary completion
2026-11
later than 40 of 89 live
Registered
339th of 353
by date

Among the 353 studies in Obesity with a site in Turkey, this one is the 126th largest by planned enrollment of the 160 observational ones that give a count, is one of 60 that started in 2026, is one of 160 observational ones, reaches primary completion later than 40 of the 89 other live ones, and was the 339th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

73 of the 353 studies in Obesity with a site in Turkey are open now. Recruiting first, the newest first:

67 more — sign in →

All 73 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 353 studies in Obesity with a site in Turkey, or all of them as a file.
02

Study summary

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GLP-1/GIP agonists such as semaglutide and tirzepatide produce marked weight loss in people with obesity, with reported reductions of about 15-20%. Rapid weight loss may reduce not only fat mass but also lean body mass and skeletal muscle mass, raising concern about sarcopenia and sarcopenic obesity. Evidence in non-diabetic obese individuals is limited and inconsistent. This prospective descriptive study will assess muscle mass, muscle strength, physical performance and sarcopenia risk in non-diabetic obese adults starting GLP-1 RA therapy, at baseline and at month 3, and will examine how weight loss relates to changes in body composition.

Read the detailed description

Adults aged 18 years or older with obesity (BMI >30 kg/m²) and without diabetes, who are referred from the Endocrinology and Metabolism and Internal Medicine outpatient clinics to the Diabetes Education Unit and are receiving a GLP-1 RA for its approved indication, will be enrolled after verbal consent. Sarcopenia screening uses the SARC-F questionnaire (strength, assistance in walking, rise from a chair, climb stairs). Muscle strength and performance are assessed by handgrip strength (hydraulic hand dynamometer, seated, elbow at 90°, three trials per hand, highest value recorded, population-specific EWGSOP2 cut-offs), the five-times chair stand test (>15 seconds indicates high risk) and 4-metre gait speed (\<0.8 m/s indicates low performance). Skeletal muscle mass index (SMMI), BMI and fat mass are obtained by bioelectrical impedance analysis (BIA), which is already performed at every routine follow-up visit. Routine laboratory results are transcribed from clinical records; no additional blood samples are requested. Assessments occur at GLP-1 RA initiation and at month 3.

03

Conditions studied

  • Obesity
  • Sarcopenia

Keywords

  • GLP-1 receptor agonist
  • Sarcopenia
  • Sarcopenic obesity
  • SARC-F Handgrip strength
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with obesity and no diabetes referred from the Endocrinology and Metabolism and Internal Medicine outpatient clinics to the Diabetes Education Unit and using a GLP-1 RA.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Diagnosis of obesity ( >30 kg/m²)
  • Currently using a GLP-1 RA
  • No hearing, speech or cognitive impairment
  • Not receiving treatment for major depressive disorder and not using antidepressants
  • Verbal consent to participate

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of diabetes
  • History of chronic kidney failure, chronic liver disease, decompensated heart failure or
  • Pregnancy or breastfeeding
  • Walking impairment
  • Not meeting inclusion criteria or unwilling to participate
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
42 participants (estimated)
Target follow-up
3 Months
Patient registry
Yes

Groups and cohorts

  • Non-diabetic obese adults receiving a GLP-1 RA (or GLP-1/GIP dual agonist) for obesity

    Adults (≥18 years) with BMI ≥30 kg/m² and no diabetes who start GLP-1 RA treatment under routine clinical care and are followed at the Diabetes Education Unit.

    Drug: GLP-1 receptor agonist (e.g., semaglutide, tirzepatide) - prescribed by the treating physician as standard care; the study does not assign or alter treatment.

Interventions

  • DrugGLP-1 receptor agonist (e.g., semaglutide, tirzepatide) - prescribed by the treating physician as standard care; the study does not assign or alter treatment.

    GLP-1 receptor agonist (GLP-1 RA) or dual GLP-1/GIP receptor agonist (e.g., semaglutide, tirzepatide) prescribed by the treating physician as routine clinical care for obesity in adults without diabetes. The agent, dose and duration are determined by the treating physician; the study does not assign, supply or modify treatment. Participants are enrolled at GLP-1 RA initiation and followed for 3 months at the Diabetes Education Unit. Study-specific assessments at baseline and month 3: SARC-F questionnaire, handgrip strength (hydraulic dynamometer), five-times chair stand test and 4-metre gait speed. Body composition by bioelectrical impedance analysis (skeletal muscle mass index, fat mass) and routine laboratory results are taken from standard clinical follow-up; no additional blood tests are requested.

This study also gives SemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., TirzepatideStudies of TirzepatideTirzepatide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Change in SARC-F (Strength, Assistance in walking, Rise from a chair, Climb stairs, and Falls) total score

    SARC-F is a 5-item sarcopenia screening questionnaire. Total score ranges from 0 to 10, and higher scores indicate a worse outcome (greater risk of sarcopenia). Change = month 3 score minus baseline score, reported in points on the scale.

    Time frame: Baseline (GLP-1 RA initiation) and 3 months

Secondary outcomes

  1. Number of participants with a positive SARC-F screening result

    Positive screening is defined as a SARC-F total score of 4 or higher (scale range 0 to 10; higher scores indicate a worse outcome). Reported as number of participants.

    Time frame: Baseline and 3 months

Other outcomes

  1. Change in handgrip strength

    Maximum handgrip strength in kilograms, measured with a hydraulic hand dynamometer (seated, elbow at 90°, three trials per hand; highest of six values used). Change = month 3 minus baseline. Higher values indicate greater strength (better outcome).

    Time frame: baseline and 3 months.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Aroda VR, Erhan U, Jelnes P, Meier JJ, Abildlund MT, Pratley R, Vilsboll T, Husain M. Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes. Diabetes Obes Metab. 2023 May;25(5):1385-1397. doi: 10.1111/dom.14990. Epub 2023 Feb 21. PubMed 36700417 ↗
  • Sargeant JA, Henson J, King JA, Yates T, Khunti K, Davies MJ. A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans. Endocrinol Metab (Seoul). 2019 Sep;34(3):247-262. doi: 10.3803/EnM.2019.34.3.247. PubMed 31565876 ↗
  • Silver HJ, Olson D, Mayfield D, Wright P, Nian H, Mashayekhi M, Koethe JR, Niswender KD, Luther JM, Brown NJ. Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes. Diabetes Obes Metab. 2023 Aug;25(8):2340-2350. doi: 10.1111/dom.15113. Epub 2023 May 15. PubMed 37188932 ↗
  • Damluji AA, Alfaraidhy M, AlHajri N, Rohant NN, Kumar M, Al Malouf C, Bahrainy S, Ji Kwak M, Batchelor WB, Forman DE, Rich MW, Kirkpatrick J, Krishnaswami A, Alexander KP, Gerstenblith G, Cawthon P, deFilippi CR, Goyal P. Sarcopenia and Cardiovascular Diseases. Circulation. 2023 May 16;147(20):1534-1553. doi: 10.1161/CIRCULATIONAHA.123.064071. Epub 2023 May 15. PubMed 37186680 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Nov 2026, 6 months after the start.

Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 6 months is below that.

Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 5, 2026
StartActual
May 30, 2026
Primary completionEst.
Nov 30, 2026
CompletionEst.
Nov 30, 2026
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Change in SARC-F score and proportion of participants screening positive for sarcopenia (SARC-F ≥4)Now Change in SARC-F (Strength, Assistance in walking, Rise from a chair, Climb stairs, and Falls) total scoreTime frame: Baseline and 3 months → Baseline (GLP-1 RA initiation) and 3 months
Oct 8, 2026
Secondary outcomes
2 edited
What changed in the outcomes
  • ChangedBefore Skeletal muscle mass index (SMMI)Now Number of participants with a positive SARC-F screening resultTime frame: baseline and 3 months. → Baseline and 3 months
  • Editedother outcomeHandgripChange in handgrip strengthTime frame: baseline and 3 months.
Oct 8, 2026
Registered
First appeared on the registry
Oct 5, 2026
Show all 2 updates
  1. Oct 8, 2026
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Change in SARC-F score and proportion of participants screening positive for sarcopenia (SARC-F ≥4)Now Change in SARC-F (Strength, Assistance in walking, Rise from a chair, Climb stairs, and Falls) total scoreTime frame: Baseline and 3 months → Baseline (GLP-1 RA initiation) and 3 months
    Secondary outcomes 2 edited
    What changed in the outcomes
    • ChangedBefore Skeletal muscle mass index (SMMI)Now Number of participants with a positive SARC-F screening resultTime frame: baseline and 3 months. → Baseline and 3 months
    • Editedother outcomeHandgripChange in handgrip strengthTime frame: baseline and 3 months.
  2. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07858864
Lead sponsor
Istanbul Saglik Bilimleri University
Responsible party
GÜLDEN ANATACA (MsD, Istanbul Saglik Bilimleri University) — Principal investigator
First posted
Oct 5, 2026
Start date
May 30, 2026
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Oct 8, 2026

Study contacts

GÜLDEN ANATACA
Contact
ganataca@yahoo.com
05059284244

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion